Abstract:Introduction: Gastrointestinal stromal tumor (GIST) is the most common human sarcoma and is typically driven by a single mutation in the Kit receptor. While highly effective, tyrosine kinase inhibitors like imatinib are not curative. The natural ligand for the Kit receptor is Kit Ligand (KitL), which exists in both soluble and membrane-bound forms. We sought to determine the role of KitL in the oncogenic Kit signaling of GIST. Methods: KitV558Δ/+ mice, which spontaneously develop an intestinal GIST, were treated with imatinib or vehicle for 1 week, and sorted non-immune (CD45-) cells from tumors were submitted for single-cell RNA sequencing (n=3/group). GIST T1 cells were treated with KitL with or without imatinib and oncogenic Kit signaling was evaluated. KitV558Δ/+ mice were crossed with various KitL mutant and inducible models and tumor weights were measured (n=3-4/group). Human GISTs were stained for KitL expression by IHC, and an existing bulk RNA sequencing human GIST dataset with matched human serum was analyzed. Results: Unsupervised clustering revealed endothelial, smooth muscle, and tumor cells had high expression of KitL RNA in untreated tumors from KitV558Δ/+ mice. Imatinib therapy increased KitL RNA in all 3 cell types, suggesting that extra-tumoral KitL expression is dependent on oncogenic signaling (p<0.05). In GIST T1 cells, exogenous KitL increased Kit activation and reduced imatinib's efficacy. Tumors from mice with homozygous KitL deletion (KitV558Δ/+;Etv1Cre-ERT2/+;KitLflox/flox) were smaller than tumors from littermates with heterozygous KitL deletion (KitV558Δ /+;Etv1Cre-ERT2/+;KitLflox/+), providing evidence that KitL contributes to GIST development in vivo despite the presence of mutated Kit (p<0.05). Furthermore, tumors from KitV558Δ/+;KitLKitL1Δ/KitL1Δ mice, which lack the proteolytic cleavage site for soluble KitL, were smaller than matched KitV558Δ/+ mice, indicating that soluble KitL is important for maximal tumor growth in vivo (p<0.05). Heterogeneous KitL expression was confirmed in human GISTs by IHC. Human serum contained more KitL in patients with tumors resistant to imatinib and in those with tumors expressing more KitL RNA(p<0.05). Conclusions: KitL is produced by multiple cell types within GIST and contributes to oncogenesis. Targeting KitL may be important for optimal tumor therapy. Citation Format: Andrew D. Tieniber, Ferdinando Rossi, Andrew Hanna, Mengyuan Liu, Mark Etherington, Kevin Do, Laura Wang, Ronald P. DeMatteo. Multiple intratumoral sources of kit ligand promote oncogenic kit signaling in gastrointestinal stomal tumor [abstract]. In: Proceedings of the AACR Special Conference: Sarcomas; 2022 May 9-12; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2022;28(18_Suppl) nr A017.

Stem Cell Factor-Mediated Wild-Type KIT Receptor Activation is Critical for Gastrointestinal Stromal Tumor Cell Growth

Expression of stem cell factor in gastrointestinal stromal tumors: Implications for proliferation and imatinib resistance.

Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.

Altered Expression of ETV1 and Its Contribution to Tumorigenic Phenotypes in Gastrointestinal Stromal Tumors.

Multiple intratumoral sources of kit ligand promote gastrointestinal stromal tumor

The microphthalmia-associated transcription factor is involved in gastrointestinal stromal tumor growth

Prognostic value of KIT mutation in gastrointestinal stromal tumors

Abstract A017: Multiple intratumoral sources of kit ligand promote oncogenic kit signaling in gastrointestinal stomal tumor

Efficacy of SCF drug conjugate targeting c-KIT in gastrointestinal stromal tumor

Identification of key genes and associated pathways in KIT/PDGFRA wild‑type gastrointestinal stromal tumors through bioinformatics analysis.

[Expression and Clinical Significance of C-Kit Oncogene in Gastrointestinal Stromal Tumors].

Comprehensive analysis of factors that involve in survival and prognosis in patients with gastrointestinal stromal tumors

[Effect of C-Kit Gene Mutation on Prognosis of Gastrointestinal Stromal Tumor].

A Novel Correlation Between KIT Promoter DNA Methylation and Prognostic of Gastrointestinal Stromal Tumors.

Co-targeting of ACK1 and KIT triggers additive anti-proliferative and -migration effects in imatinib-resistant gastrointestinal stromal tumors

The Expression of KIT Receptor Dimers in Gastrointestinal Stromal Tumors Independent of C-Kit Mutation and SCF Expression is Associated with High-Risk Stratification

C-kit gene mutation in human gastrointestinal stromal tumors.

Targeting the WEE1 Kinase Strengthens the Antitumor Activity of Imatinib Via Promoting KIT Autophagic Degradation in Gastrointestinal Stromal Tumors

Discovery of a highly selective KIT kinase primary V559D mutant inhibitor for gastrointestinal stromal tumors (GISTs).

DDR1/2 enhance KIT activation and imatinib resistance of primary and secondary KIT mutants in gastrointestinal stromal tumors

DDR1/2 Enhance KIT Activation and Imatinib Resistance of Primary and Secondary KIT Mutants in Gastrointestinal Stromal Tumors.